# Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant

> **NCT03622775** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma

## Interventions

- **BIOLOGICAL:** Daratumumab

## Key facts

- **NCT ID:** NCT03622775
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-11
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-10-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03622775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03622775, "Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03622775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*